CARA Therapeutics
ISIN US1407551092
|WKN A1XDTK
Overview
Description
CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Its portfolio includes opioid-based products, anesthetic-based drugs, and analgesics that targets to alleviate itch and pain. The company was founded by Derek T. Chalmers, Michael E. Lewis, and Frederique Menzaghi on July 2, 2004 and is headquartered in Stamford, CT.
Healthcare Biopharmaceuticals System-Specific Biopharmaceuticals United States
Financials
Key metrics
| Market capitalisation, EUR | 34.27 m |
| EPS, EUR | -2.02 |
| P/B ratio | 0.67 |
| P/E ratio | - |
| Dividend yield | 0.00% |
Income statement (2023)
| Revenue, EUR | 19.40 m |
| Net income, EUR | -109.62 m |
| Profit margin | -565.21% |
What ETF is CARA Therapeutics in?
There are 2 ETFs which contain CARA Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of CARA Therapeutics is the CSIF (IE) MSCI USA Small Cap ESG Leaders Blue UCITS ETF B USD.
| ETF | Weight | Investment focus | Holdings | TER | Fund size (in m EUR) | Return 1Y | WKN | ISIN |
|---|---|---|---|---|---|---|---|---|
| CSIF (IE) MSCI USA Small Cap ESG Leaders Blue UCITS ETF B USD | 0.02% | Equity United States Small Cap | 723 | 0.20% | 440 | +19.05% | A2P4U1 | IE00BMDX0L03 |
| SPDR Russell 2000 US Small Cap UCITS ETF | 0.00% | Equity United States Small Cap | 1,795 | 0.30% | 2,536 | +20.43% | A1XFN1 | IE00BJ38QD84 |
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH. Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.